Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650154 | 0.72 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL2578714 | 0.69 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL10525369 | 0.69 | — | — | |
| SCHEMBL3305710 | 0.67 | — | — | |
| SCHEMBL526564 | 0.67 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL16036122 | 0.67 | — | — | |
| SCHEMBL476033 | 0.67 | — | — | |
| SCHEMBL3002382 | 0.67 | — | — | |
| SCHEMBL3261337 | 0.67 | — | — | |
| SCHEMBL6057564 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | claimed |
| EP-1865968-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1768982-A2 | PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | Amgen Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006102604-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006004703-A2 | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| EP-2437854-B1 | COMPOSITIONS COMPRISING BORINIC ESTERS | COLGATE PALMOLIVE CO (US) | 2018-08-08 | — | — | EP | disclosed |
| US-8852559-B2 | Borinic compositions | COLGATE-PALMOLIVE COMPANY (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2437855-A2 | BORINIC COMPOSITIONS | Colgate-Palmolive Company (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2437854-A2 | BORINIC COMPOSITIONS | Colgate-Palmolive Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120064017-A1 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120052025-A1 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1768982-A2 | PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006102604-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004703-A2 | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | LCK, ADCK1, DCK | ALDH1A1 4270/4885 |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | CUTA, BROX, BTD | ALDH1A1 1150/4885 |
| US-20120064017-A1 | BORINIC COMPOSITIONS | BACH1, FHIT, BPNT1 | ALDH1A1 4175/4885 |
| US-20120052025-A1 | BORINIC COMPOSITIONS | CCL11, BDKRB2, BTD | ALDH1A1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.